Fisher Wallace Labs is a medical and wellness device company that developed the technology that powers Circadia®. Over 100,000 patients have used the company’s neuromodulation medical devices which have been prescribed by over 14,000 providers. Circadia® uses the same neuromodulation technology as the company’s medical device, but is the company’s wellness brand strictly intended for stress and sleep management, and does not require a prescription. Fisher Wallace was recently named one of “5 Health-Tech Startups to Watch” by Entrepreneur magazine and “One of Four Technologies Innovating Mental Health” by Forbes.
Co-Founder & CEO
For more than a decade, Kelly Roman has helped pioneer the prescription wearable category and has expertise in product development, regulatory affairs, healthcare marketing and clinical trial strategy.
Prior to co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries. He recently served on the boards of two charter high schools in New York City.
Co-Founder & Chairman
Charles “Chip” Fisher grew up in the electronics business - his father, Avery Fisher, founded Fisher Radio (later renamed Fisher Electronics).
After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s CFO and largest shareholder - and a recent TEDx contributor.
Advisor
Peter is currently Head of Product, NPE, at Meta, where he incubates the company's new and experimental products. Previously, Peter was a Partner at Betaworks Ventures, which invested in Giphy (sold to Facebook) among other startups, and co-founded the popular tech blogs Engadget and Gizmodo.
Board Member
Simon is CEO of SHUFL Capital, the venture capital firm that recently invested in Fisher Wallace Laboratories. Simon's early career was spent in the UK financial services sector leading business change, delivering technology transformations and supporting M&A transactions.
He led CPA Global on its 20 year journey from a £50m business to its recent public market entry at a value of £6.5bn. Simon has been investing in and working with founders of growth businesses in the SHUFL sectors since 2010.
M.D., FRCPC
Meir Kryger, MD, FRCPC, joined the Yale School of Medicine and the VA Connecticut Health System, November 2011. Previously he was Professor of Medicine, University of Manitoba where he established the first clinical laboratory studying patients with sleep breathing problems in Canada.
Dr. Kryger has published more than 200 research articles and book chapters. He is the chief editor of the most widely used textbook in sleep medicine, The Principles and Practice of Sleep Medicine, currently in its 5th edition.
M.D.
Mitchell S. “Mitch” Rosenthal, M.D. is president of the Rosenthal Center for Addiction Studies. A pioneer in the treatment of substance abuse, Dr. Rosenthal was founder of Phoenix House, the nation's leading private, non-profit provider of substance abuse services. He began work in the field in 1965 as a psychiatrist at the U.S. Naval Hospital in Oakland, California (1965-1967), where he established the first service-sponsored therapeutic community, successfully treating both alcoholics and drug addicts.
As a leading advocate for the treatment community, Dr. Rosenthal chaired the New York State Advisory Council on Substance Abuse from 1985 to 1997. He has been a White House advisor on drug abuse and a special consultant to the Office of National Drug Control Policy. He is a lecturer in psychiatry at Columbia University College of Physicians and Surgeons, and was awarded an honorary degree (Doctor of Humane Letters) by SUNY Downstate Medical Center in 2002.
M.D.
Dr. Xenakis served 28 years in the United States Army as a medical corps officer. He held a wide variety of assignments as a clinical psychiatrist, staff officer, and senior commander including Commanding General of the Southeast Army Regional Medical Command.
Dr. Xenakis has written widely on medical ethics, military medicine, and the treatment of detainees. He has published editorials in the Washington Post and a number of other national magazines and journals, including book chapters and legal reviews. Dr. Xenakis has an active clinical and consulting practice, and is currently working on the clinical applications of quantitative electroencephalography (QEEG) to brain injury and other neurobehavioral conditions.
M.D.
Dr. Liskin is Clinical Assistant Professor of Psychiatry at Weill Cornell Medical College and on the attending staff at New York Presbyterian Hospital. Dr. Liskin entered medicine with a foundation in neuroscience and neurobehavioral research. She was the recipient of a Howard Hughes Medical Institute Award and published electrophysiology research on Circadian Rhythms.
She did her Psychiatry residency training at Cornell, a Forensic Psychiatry fellowship at Albert Einstein College of Medicine, and completed the Psychodynamic Psychotherapy program at the Columbia Center for Psychoanalytic Training & Research. She has been in private practice in New York City since 1999. She currently serves on the American Psychiatric Association's New York State District Branch Practice Committee as well as its Integrative Psychiatry Task Force.
